CYCLERION THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • March 5th, 2024 • Cyclerion Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences the grant of shares of restricted Stock by Cyclerion Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan (as amended from time to time, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
Cyclerion Therapeutics, Inc.Recognition Bonus Agreement • March 5th, 2024 • Cyclerion Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This letter agreement (this “Agreement”) between you and Cyclerion Therapeutics, Inc. (the “Company”) amends and restates the prior retention bonus letter agreement, dated October 3, 2022, between you and the Company, with respect to your opportunity to earn a Recognition Bonus (as defined below). The Company is offering you this opportunity in recognition of your importance to the continued success of the Company.
CONSULTING AGREEMENT Cyclerion Contract # __________Consulting Agreement • March 5th, 2024 • Cyclerion Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (this “Agreement”) made as of December 1, 2023 (the “Effective Date”) is between Cyclerion Therapeutics, Inc., a Massachusetts corporation having an address at 245 First Street, 18th Floor , Cambridge, MA 02142 (“Cyclerion”), and Peter Hecht, Ph.D. (“Consultant”).
